What Scleral Lenses Teach Us About Ocular Surface Protection
Scleral lenses are not a cure for oGVHD, but they teach an important lesson about ocular surface protection.
Unlike standard contact lenses, scleral lenses vault over the cornea and rest on the sclera, the white part of the eye. This design can create a fluid reservoir over the corneal surface. In patients with severe ocular surface disease, that reservoir may help protect the cornea, reduce exposure-related stress, improve comfort, and stabilize vision.
The broader lesson is that oGVHD may require more than intermittent wetting. The ocular surface may need sustained protection from desiccation, friction, exposure, and epithelial stress.
That concept is important because oGVHD can compromise several protective systems at once. Tear production may decline. Tear-film quality may worsen. Blinking may become less effective or more abrasive. The conjunctiva may scar. The corneal epithelium may become fragile. Eyelid disease may increase mechanical irritation.
Under those conditions, simply adding moisture from time to time may not fully address the problem. The surface may need a more durable protective environment. Scleral lenses also show why visual function matters. If the tear film is unstable or the corneal surface is irregular, vision may fluctuate. A fluid reservoir and smoother optical surface may help some patients see more consistently.
However, scleral lenses are not appropriate for every patient. They require specialized fitting, careful hygiene, monitoring, insertion and removal training, and ongoing care. Some patients may face barriers related to cost, access, dexterity, ocular anatomy, infection risk, or tolerance.
The point is not that every oGVHD patient should use scleral lenses, rather that ocular surface protection is a serious therapeutic principle.
For researchers, scleral lenses raise broader questions. How much of oGVHD symptom burden is driven by exposure and friction? How much surface protection is needed to support epithelial healing? Which approaches protect the ocular surface while also reducing treatment burden? How can therapy address both protection and disease biology?
For patients and advocates, scleral lenses offer a useful framework. oGVHD is not only about dryness. It is about the failure of the eye’s protective surface environment. Protecting that surface may be central to preserving comfort, clarity, and function.
This article is for educational purposes only and is not medical advice.
Sources:
- Jones L, Downie LE, Korb D, et al. “TFOS DEWS II Management and Therapy Report.” The Ocular Surface, 2017.
https://www.tfosdewsreport.org/report-management_and_therapy/147_36/en/ - Tappeiner C, Heiligenhaus A, Halter JP, et al. “Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.” Frontiers in Medicine, 2023.
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1133381/full - Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. “Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation.” Biology of Blood and Marrow Transplantation, 2019.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6362842/
